{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:38:22Z","timestamp":1777012702323,"version":"3.51.4"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Antibodies mediate a wide range of antiviral functions, including neutralization and diverse Fc-dependent effector activities. Among these, antibody-dependent cellular phagocytosis (ADCP) has emerged as an important mechanism contributing to pathogen clearance, including during HIV-1 infection. Conventional bead-based ADCP assays typically rely on recombinant envelope glycoprotein (Env), which offers practical advantages but fails to fully recapitulate the native structural, conformational, and glycan features of virion-associated Env. This limitation reduces the physiological relevance of these assays for evaluating antibody function\n                      <jats:italic>in vivo<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a virus particle-based ADCP assay designed to preserve the native membrane-embedded conformation and glycosylation of HIV-1 Env. The assay uses sucrose-purified, inactivated HIV-1 virions coupled to fluorescent beads as phagocytic targets, and the THP-1 human monocytic cell line as effector cells. The assay was optimized for sensitivity, reproducibility, and high\u2011throughput compatibility, and was applied to evaluate ADCP responses mediated by both monoclonal and polyclonal antibodies across multiple species.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The virus particle-based ADCP assay enabled robust and reproducible measurement of antibody-mediated phagocytosis in a biologically relevant antigen format. Using this system, we observed Env isolate-specific differences in Fc\u2011mediated activity that were not fully captured using recombinant gp120\u2011based assays. Direct comparison revealed that ADCP readouts obtained with recombinant Env proteins did not consistently mirror those measured using native virion-associated Env, highlighting qualitative differences in antibody engagement and Fc effector function depending on antigen presentation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      These findings demonstrate that preservation of native Env structure and glycosylation is critical for accurate assessment of Fc-dependent effector functions such as ADCP. The virus particle-based assay described here provides a practical and scalable framework for functional profiling of antibody responses in the context of HIV-1 infection and vaccination. By revealing antigen context-dependent differences in Fc\u2011mediated activity, this approach reinforces the importance of using antigenically authentic, virion-based systems to better reflect\n                      <jats:italic>in vivo<\/jats:italic>\n                      antibody function and inform vaccine and immunotherapeutic strategies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1809342","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:43:08Z","timestamp":1777009388000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Virus particle-based antibody-dependent cellular phagocytosis assay for HIV"],"prefix":"10.3389","volume":"17","author":[{"given":"Chitra","family":"Upadhyay","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai","place":["New York, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka Gadam","family":"Rao","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai","place":["New York, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01187-17","article-title":"Protective efficacy of broadly neutralizing antibodies with incomplete neutralization activity against simian-human immunodeficiency virus in rhesus monkeys","volume":"91","author":"Julg","year":"2017","journal-title":"J Virol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.75.17.8340-8347.2001","article-title":"Antibody protects macaques against vaginal challenge with a pathogenic R5 simian\/human immunodeficiency virus at serum levels giving complete neutralization in vitro","volume":"75","author":"Parren","year":"2001","journal-title":"J Virol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"243ra88","DOI":"10.1126\/scitranslmed.3008992","article-title":"Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor","volume":"6","author":"Pegu","year":"2014","journal-title":"Sci Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132494","article-title":"Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques","volume":"211","author":"Shingai","year":"2014","journal-title":"J Exp Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1146\/annurev-immunol-080219-023629","article-title":"Vaccines and broadly neutralizing antibodies for HIV-1 prevention","volume":"38","author":"Stephenson","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2031738","article-title":"Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01953-6","article-title":"Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition","volume":"28","author":"Gilbert","year":"2022","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.chom.2019.08.014","article-title":"A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge","volume":"26","author":"Pegu","year":"2019","journal-title":"Cell Host Microbe"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-025-01206-6","article-title":"The HIV-1 envelope glycoprotein: structure, function and interactions with neutralizing antibodies","volume":"23","author":"Klasse","year":"2025","journal-title":"Nat Rev Microbiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"228ra38","DOI":"10.1126\/scitranslmed.3007736","article-title":"Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines","volume":"6","author":"Chung","year":"2014","journal-title":"Sci Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01667-20","article-title":"Systematic assessment of antiviral potency, breadth, and synergy of triple broadly neutralizing antibody combinations against simian-human immunodeficiency viruses","volume":"95","author":"Berendam","year":"2021","journal-title":"J Virol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.106015","article-title":"Functional comparison of Fc-engineering strategies to improve anti-HIV-1 antibody effector functions","volume":"231","author":"Schriek","year":"2024","journal-title":"Antiviral Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006987","article-title":"HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies","volume":"14","author":"Richardson","year":"2018","journal-title":"PloS Pathog"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.734304","article-title":"Contribution to HIV prevention and treatment by antibody-mediated effector function and advances in broadly neutralizing antibody delivery by vectored immunoprophylaxis","volume":"12","author":"Phelps","year":"2021","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2017.10.007","article-title":"Impact of HIV-1 envelope conformation on ADCC responses","volume":"26","author":"Richard","year":"2018","journal-title":"Trends Microbiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2011.03.012","article-title":"Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals","volume":"415","author":"Dugast","year":"2011","journal-title":"Virology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.10.027","article-title":"Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology","volume":"163","author":"Chung","year":"2015","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/jci126391","article-title":"Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk","volume":"129","author":"Neidich","year":"2019","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1013705","article-title":"Candidate correlates of protection in the HVTN505 HIV-1 vaccine efficacy trial identified by positive-unlabeled learning","volume":"21","author":"Xu","year":"2025","journal-title":"PloS Comput Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.09.061","article-title":"Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys","volume":"155","author":"Barouch","year":"2013","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab3886","article-title":"Protective efficacy of adenovirus\/protein vaccines against SIV challenges in rhesus monkeys","volume":"349","author":"Barouch","year":"2015","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","article-title":"A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples","volume":"366","author":"Ackerman","year":"2011","journal-title":"J Immunol Methods"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005817","article-title":"Antibody-mediated internalization of infectious HIV-1 virions differs among antibody isotypes and subclasses","volume":"12","author":"Tay","year":"2016","journal-title":"PloS Pathog"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02441","article-title":"Modulation of antibody responses to the V1V2 and V3 regions of HIV-1 envelope by immune complex vaccines","volume":"9","author":"Hioe","year":"2018","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010183","article-title":"Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice","volume":"18","author":"Hioe","year":"2022","journal-title":"PloS Pathog"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1271686","article-title":"Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1","volume":"14","author":"Hioe","year":"2023","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1476924","article-title":"Signal peptide exchange alters HIV-1 envelope antigenicity and immunogenicity","volume":"15","author":"Upadhyay","year":"2024","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01625-21","article-title":"Evolution of antibodies to native trimeric envelope and their Fc-dependent functions in untreated and treated primary HIV infection","volume":"95","author":"Nagel","year":"2021","journal-title":"J Virol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583820","article-title":"Polyfunctional Fc dependent activity of antibodies to native trimeric envelope in HIV elite controllers","volume":"11","author":"Kant","year":"2020","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012665","article-title":"Potent broadly neutralizing antibodies mediate efficient antibody-dependent phagocytosis of HIV-infected cells","volume":"20","author":"Snow","year":"2024","journal-title":"PloS Pathog"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006793","article-title":"Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis","volume":"13","author":"Gach","year":"2017","journal-title":"PloS Pathog"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00332","article-title":"Antibody-dependent cellular phagocytosis in antiviral immune responses","volume":"10","author":"Tay","year":"2019","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0504812102","article-title":"Visualization of retrovirus budding with correlated light and electron microscopy","volume":"102","author":"Larson","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.72.4.2855-2864.1998","article-title":"Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1","volume":"72","author":"Platt","year":"1998","journal-title":"J Virol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.06157-11","article-title":"Generation of transmitted\/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages","volume":"86","author":"Ochsenbauer","year":"2012","journal-title":"J Virol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009185","article-title":"Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes","volume":"16","author":"Upadhyay","year":"2020","journal-title":"PloS Pathog"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/science.1213782","article-title":"Increasing the potency and breadth of an HIV antibody by using structure-based rational design","volume":"334","author":"Diskin","year":"2011","journal-title":"Science"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1089\/08892220152741450","article-title":"A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1","volume":"17","author":"Stiegler","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.68.12.8312-8320.1994","article-title":"Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1","volume":"68","author":"Gorny","year":"1994","journal-title":"J Virol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.virol.2012.02.003","article-title":"Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals","volume":"427","author":"Gorny","year":"2012","journal-title":"Virology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.74.15.7096-7107.2000","article-title":"Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M","volume":"74","author":"Nyambi","year":"2000","journal-title":"J Virol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.78.10.5205-5215.2004","article-title":"The V1\/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection","volume":"78","author":"Pinter","year":"2004","journal-title":"J Virol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.66.12.7538-7542.1992","article-title":"Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody","volume":"66","author":"Gorny","year":"1992","journal-title":"J Virol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02202-05","article-title":"Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1","volume":"80","author":"Gorny","year":"2006","journal-title":"J\u00a0Virol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010254","article-title":"Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes","volume":"5","author":"Hioe","year":"2010","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.73.3.1974-1979.1999","article-title":"Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins","volume":"73","author":"Gigler","year":"1999","journal-title":"J Virol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/n35101999","article-title":"Identification of the cellular receptor for anthrax toxin","volume":"414","author":"Bradley","year":"2001","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2015.0286","article-title":"Monitoring HIV-1 Group M subtypes in Yaounde, Cameroon reveals broad genetic diversity and a novel CRF02_AG\/F2 infection","volume":"32","author":"Courtney","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006812","article-title":"Alterations of HIV-1 envelope phenotype and antibody-mediated neutralization by signal peptide mutations","volume":"14","author":"Upadhyay","year":"2018","journal-title":"PloS Pathog"},{"key":"B55","doi-asserted-by":"publisher","first-page":"7992","DOI":"10.1128\/jvi.72.10.7992-8001.1998","article-title":"Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins","volume":"72","author":"Rossio","year":"1998","journal-title":"J Virol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12977-015-0207-z","article-title":"Discrete partitioning of HIV-1 Env forms revealed by viral capture","volume":"12","author":"Stieh","year":"2015","journal-title":"Retrovirology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.20.524996","article-title":"Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells","volume":"97","author":"Rao","year":"2023","journal-title":"J Virol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"903","DOI":"10.21203\/rs.3.rs-829888\/v1","article-title":"Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines","volume":"13","author":"Weiss","year":"2022","journal-title":"Nat Commun"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000001038","article-title":"Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women","volume":"30","author":"Mkhize","year":"2016","journal-title":"AIDS"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01843-17","article-title":"HIV-1 envelope glycoproteins from diverse clades differentiate antibody responses and durability among vaccinees","volume":"92","author":"Yates","year":"2018","journal-title":"J Virol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.147.8.2657","article-title":"Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG","volume":"147","author":"Lund","year":"1991","journal-title":"J Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260954","article-title":"Fc-engineered antibodies with immune effector functions completely abolished","volume":"16","author":"Wilkinson","year":"2021","journal-title":"PloS One"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng Des Sel"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149766","article-title":"Specificity of mouse and human Fcgamma receptors and their polymorphic variants for IgG subclasses of different species","volume":"52","author":"Wang","year":"2022","journal-title":"Eur J Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41541-020-00223-1","article-title":"Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations","volume":"5","author":"Martin","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1013614","article-title":"Induction of HIV-1-specific antibody-mediated effector functions by native-like envelope trimers in humans","volume":"21","author":"Grobben","year":"2025","journal-title":"PloS Pathog"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670561","article-title":"Polyclonal broadly neutralizing antibody activity characterized by CD4 binding site and V3-glycan antibodies in a subset of HIV-1 virus controllers","volume":"12","author":"Nyanhete","year":"2021","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01080-18","article-title":"SOSIP changes affect human immunodeficiency virus type 1 envelope glycoprotein conformation and CD4 engagement","volume":"92","author":"Alsahafi","year":"2018","journal-title":"J Virol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007920","article-title":"Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics","volume":"15","author":"Torrents de la Pena","year":"2019","journal-title":"PloS Pathog"},{"key":"B70","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1038\/s41467-018-06121-4","article-title":"Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer","volume":"9","author":"Cao","year":"2018","journal-title":"Nat Commun"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01709-18","article-title":"Conformational differences between functional human immunodeficiency virus envelope glycoprotein trimers and stabilized soluble trimers","volume":"93","author":"Castillo-Menendez","year":"2019","journal-title":"J Virol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01369-20","article-title":"Dual pathways of human immunodeficiency virus type 1 envelope glycoprotein trafficking modulate the selective exclusion of uncleaved oligomers from virions","volume":"95","author":"Zhang","year":"2021","journal-title":"J Virol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01645-15","article-title":"Structure\/function studies involving the V3 region of the HIV-1 envelope delineate multiple factors that affect neutralization sensitivity","volume":"90","author":"Zolla-Pazner","year":"2016","journal-title":"J Virol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1104840108","article-title":"Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer","volume":"108","author":"Liu","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/nri2801","article-title":"Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design","volume":"10","author":"Zolla-Pazner","year":"2010","journal-title":"Nat Rev Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1809342\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:43:10Z","timestamp":1777009390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1809342\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":75,"alternative-id":["10.3389\/fimmu.2026.1809342"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1809342","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"article-number":"1809342"}}